510(k) · Cleared
ClearedEquimatrix
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Luitpold Pharmaceuticals, Inc. · NPM Bone Grafting Material, Animal Source
Cleared on Sep 29, 2011 as substantially equivalent to K871773 (Geistlich-Pharma, 1987) and 3 other predicates after a 94-day review. Its family tree reaches back 2 generations to 1987. 1 later device descends from it.
- Decided
- Sep 29, 2011
- Review
- 94 days
- Class
- Class II
- Product code
- NPM
- Recalls
- None
- Predicates
- 4
Its longest line of descent runs back 2 generations to K871773 (1987). 8 ancestors in all. 1 later device descends from it, 1 citing it directly.
- Root · 2 generations backK871773 Bio-Oss Pure Nat Hydroxyapatite Endoss ImplantGeistlich-Pharma · 1987
- 1 generation backK033815 Bio-Oss, Bio-Oss Blocks and Bio-Oss CollagenGeistlich-Pharma · 2004
- This deviceK111816 EquimatrixLuitpold Pharmaceuticals, Inc. · 2011
- Descendant · cites it directly · 0 of its ownK123876 SynergyOdontit S.A. · 2014
Most influential descendants
Showing 1 of 1 · See all- K123876SynergyOdontit S.A. · 2014 · cites it directly0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −2 | K871773 | Bio-Oss Pure Nat Hydroxyapatite Endoss Implant | Geistlich-Pharma | 1987 | — |
| −1 | K033815 | Bio-Oss, Bio-Oss Blocks and Bio-Oss Collagen | Geistlich-Pharma | 2004 | — |
| 0 (this device) | K111816 | Equimatrix | Luitpold Pharmaceuticals, Inc. | 2011 | — |
| +1 | K123876 | Synergy | Odontit S.A. | 2014 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 1992 | 1 | 0 |
| 1995 | 2 | 0 |
| 1998 | 2 | 0 |
| 2000 | 1 | 0 |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2014 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in NPM? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new NPM device
- #1 K240661 Geistlich Bio-Oss®score 15.2 · 6 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (4)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K871773 | Bio-Oss Pure Nat Hydroxyapatite Endoss ImplantSummary page 1…Animal Source Dental Bone Grafting Material Predicate Device Bio-Oss® natural bone grafting material (K871773, K952617, K970321, K033815) Manufactured by: Geistlich Pharma AG Bahnhofstrasse 4… | 1987 |
| * | K952617 | Bio-OssSummary page 1…imal Source Dental Bone Grafting Material Predicate Device Bio-Oss® natural bone grafting material (K871773, K952617, K970321, K033815) Manufactured by: Geistlich Pharma AG Bahnhofstrasse 40… | 1995 |
| * | K970321 | Bio-Oss Anorganic Bovine BoneSummary page 1…ne Grafting Material Predicate Device Bio-Oss® natural bone grafting material (K871773, K952617, K970321, K033815) Manufactured by: Geistlich Pharma AG Bahnhofstrasse 40 CH-61 10 Wolhuse… | 1998 |
| * | K033815 | Bio-Oss, Bio-Oss Blocks and Bio-Oss CollagenSummary page 1…ng Material Predicate Device Bio-Oss® natural bone grafting material (K871773, K952617, K970321, K033815) Manufactured by: Geistlich Pharma AG Bahnhofstrasse 40 CH-61 10 Wolhusen… | 2004 |
What descends from it? (1)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K123876 | Synergy | 2014 | 0 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 24 years and passes through 2 companies; a new generation was cleared every 16.4 years on median.
- None of the 8 ancestors has a recall.
- Of its descendants, K123876 (Odontit S.A., 2014) has gone furthest, with 0 descendants of its own.
- 3 other devices also cite its predicate K871773.
How does its category compare?
All NPM devicesNPM Bone Grafting Material, Animal Source: FDA decisions, review times, recalls and adverse event reports over 20 years. 2011, this device’s year, is highlighted.
FDA decisions per year · NPM
3in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · NPM
30in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · NPM
1in 2022
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · NPM
14in 2025
MAUDE reports naming product code NPM, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 1 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 1 | — | 0 | 0 |
| 2010 | 2 | — | 0 | 1 |
| 2011 | 3 | 112 | 0 | 0 |
| 2012 | 2 | — | 0 | 2 |
| 2013 | 2 | — | 0 | 3 |
| 2014 | 2 | — | 0 | 3 |
| 2015 | 4 | 349 | 0 | 1 |
| 2016 | 1 | — | 0 | 1 |
| 2017 | 5 | 191 | 0 | 3 |
| 2018 | 2 | — | 1 | 8 |
| 2019 | 0 | — | 0 | 6 |
| 2020 | 3 | 231 | 3 | 3 |
| 2021 | 2 | — | 0 | 4 |
| 2022 | 0 | — | 1 | 27 |
| 2023 | 2 | — | 0 | 4 |
| 2024 | 3 | 211 | 0 | 5 |
| 2025 | 3 | 30 | 0 | 14 |
| 2026 | 3 | 269 | 0 | — |
What is it indicated for?
EQUIMATRIX Th cancellous and cortical granules are recommended for:
- Augmentation or reconstructive treatment of the alveolar ridge.
- Filling of infirabony periodontal defects.
- Filling of defects after root resection, apicoectomy, and cystectomy.
- Filling of extraction sockets to enhance preservation of the alveolar ridge.
- Elevation of the maxillary sinus floor.
- Filling of periodontal defects in conjunction with products intended for Guided Tissue Regeneration (GTR) and Guided Bone Regeneration (GBR).
- Filling of peri-implant defects in conjunction with products intended for Guided Bone Regeneration (GBR).
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K111816 · printed Nov 6, 2026
Cite this page
510(k) Report. “K111816: Equimatrix.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K111816
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026